Michel has served as our Chief Executive Officer and a director since our inception. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012. Prior to that, Michel worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).
Michel holds a degree in biochemistry and a Ph.D. in Biochemistry from Université Catholique de Louvain and a business certificate from Solvay Business School.
Matthew joined iTeos Therapeutics in 2019 as Chief Operating Officer. He has nearly 20 years’ experience in business development and corporate strategy leadership roles in the biotech space. Prior to joining iTeos, Matt served as Chief Operating Officer at Endocyte, a Novartis company, leading all business functions. He led all strategic partnering and licensing activities resulting in numerous successful transactions, including Endocyte’s transformational in-license of PSMA-617, which led to the $2.1 billion acquisition of Endocyte by Novartis. Matt managed Endocyte’s billion-dollar out-licensing partnership with Merck and sat on the Joint Development and Joint Commercialization Committees. During his tenure at Endocyte, Matt also supervised new product planning, strategic planning, project management and marketing. Matt started his career in corporate strategy, business development and alliance management in the high tech space.
He has a BA from Brigham Young University and an MBA from Purdue University.
Jo joined iTeos as Chief Medical Officer in April 2019.
Before joining iTeos, Jo had more than 15 years of experience in Oncology drug development at GSK and Sanofi, most recently as the Head of Global Oncology Development at Sanofi. Here, she was responsible for the entire Oncology portfolio from preclinical development through to post-marketing commitments and life-cycle management, significantly rebuilding the portfolio during her five years in this role. Jo earned her M.D. and trained as a Pediatric Hematologist/Oncologist at Duke University and practiced Pediatric Blood and Marrow Transplantation at Duke University Hospital. She has authored or co-authored 20 peer-reviewed publications.
Matthew joined iTeos from Sarepta Therapeutics, Inc. in June 2020 where he was the Senior Vice President of Corporate Development and Treasurer and where he led the Company’s recent partnering process with Roche, resulting in a multibillion dollar collaboration agreement and raised over $2billion from capital markets. During his 15 year career in biotech financial management and corporate development, Matthew also worked at Celgene and Gilead Sciences. Matthew has an MBA from the University of Chicago Booth School of Business.
Yvonne joined iTeos in 2020 as Vice-President of Research & Development. With more than 20 years of international experience in oncology drug discovery and development, she has taken lead candidates from early stage research into clinical trials. Immediately prior to iTeos, she served as CSO and board member in Complix, a company developing novel biologics. She has also lead R&D activities in UK based biotech companies including Immunocore and Biovex.
Yvonne holds a PhD from the University of Wales, College of Medicine.
Philippe joined iTeos in January 2020 as Vice-President, Human Resources. In this role, he is responsible for all aspects of Human Resources, implementing reward and talent management strategies that support the achievement of business goals and objectives while driving employee engagement.
Philippe Brantegem joined iTeos from Korn Ferry where he was advising international clients on people and organizational strategy. Philippe brings more than 20 years of experience in Human Resources Management, has served in different management and advisory functions in Biopharmaceutical companies such as Sanofi Pasteur MSD, Besins Heathcare, Merck and GSK.
Philippe has master degrees in Human Resources Management and in Public Administration from the University of Brussels – Belgium (ULB - Solvay).